PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19199981-6 2009 Randomized trials of rimonabant in patients with overweight or obesity and/or type 2 diabetes have demonstrated marked and significant improvements in body weight, waist circumference, glycemic control (in patients with type 2 diabetes), features of atherogenic dyslipidemia, insulin resistance, adipose tissue-derived cytokines (leptin and adiponectin) and C-reactive protein (a marker of systemic inflammation). Rimonabant 21-31 insulin Homo sapiens 276-283 22170727-11 2012 CONCLUSIONS: Improvements observed in insulin regulation of free fatty acid and glucose metabolism with rimonabant treatment in humans was not greater than that predicted by weight loss alone. Rimonabant 104-114 insulin Homo sapiens 38-45 21564446-0 2011 Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Rimonabant 0-10 insulin Homo sapiens 33-40 20009090-1 2010 OBJECTIVE To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. Rimonabant 48-58 insulin Homo sapiens 155-162 19275673-5 2009 Conversely, rimonabant, the first selective CB(1) receptor antagonist in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and to increase HDL cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Rimonabant 12-22 insulin Homo sapiens 177-184 18410553-11 2008 CONCLUSION: This study suggests that the weight loss through rimonabant therapy may be of use in patients with PCOS and appears superior to insulin sensitization by metformin in reducing the FAI and insulin resistance in obese PCOS patients treated over a 12-week period. Rimonabant 61-71 insulin Homo sapiens 199-206 18426513-2 2008 Rimonabant 20 mg daily consistently reduced body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and increased HDL cholesterol concentrations in both non-diabetic and type-2 diabetic overweight/obese patients. Rimonabant 0-10 insulin Homo sapiens 109-116 18551116-3 2008 We examined effects of the natural CB1 agonist, 2-Arachidonoylglycerol (2-AG), and the synthetic CB1 antagonist, SR141716, on insulin action in cultured adipocytes. Rimonabant 113-121 insulin Homo sapiens 126-133 18551116-5 2008 2-AG activation of the CB1 receptor promoted insulin sensitivity whereas antagonism by SR141716 reduced insulin sensitivity. Rimonabant 87-95 insulin Homo sapiens 104-111 18551116-7 2008 Consistent with these results we found that insulin-stimulated phosphorylation of the protein kinase Akt was increased by 2-AG, attenuated by SR141716, and unaffected in the absence of insulin or by addition of high-dose insulin. Rimonabant 142-150 insulin Homo sapiens 44-51 18814765-4 2008 Rimonabant, a selective antagonist of CBI receptors, improves glucose control in patients with type 2 diabetes, treated with diet alone, metformin, sulfonylurea or insulin, while it also reduces body weight and other risk factors. Rimonabant 0-10 insulin Homo sapiens 164-171 18417461-5 2008 Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 0-10 insulin Homo sapiens 171-178 18417461-5 2008 Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 0-10 insulin Homo sapiens 187-194 18426514-3 2008 Patients treated with rimonabant also demonstrated statistically significant improvement in high-density lipoprotein cholesterol levels, triglyceride levels and insulin resistance, as well as a reduced overall prevalence of metabolic syndrome. Rimonabant 22-32 insulin Homo sapiens 161-168 18194939-6 2007 In several studies, rimonabant (20 mg daily) demonstrated a favorable effect on various risk factors for cardiovascular disease, including dyslipidemia, abdominal obesity, insulin resistance, blood pressure, and measures of inflammation. Rimonabant 20-30 insulin Homo sapiens 172-179 18635590-4 2008 Rimonabant is the first type-1 endocannabinoid receptor blocker that has been shown to improve the serum lipid profile, insulin and glucose levels, and blood pressure. Rimonabant 0-10 insulin Homo sapiens 120-127 18303686-3 2008 Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight loss, reduces waist circumference, improves atherogenic dyslipidaemia (low HDL cholesterol, high triglycerides, high small dense LDL), diminishes insulin resistance, reduces HbA1c levels, and contributes to lower blood pressure and C-reactive protein levels. Rimonabant 50-60 insulin Homo sapiens 248-255 18154742-8 2007 In addition, rimonabant was associated with favorable changes in several other cardiometabolic risk factors, including significant increases in serum levels of high-density lipoprotein cholesterol and adiponectin, as well as reductions in serum levels of triglycerides, small, dense low-density lipoprotein particles, C-reactive protein, insulin resistance, and glycosylated hemoglobin. Rimonabant 13-23 insulin Homo sapiens 338-345 18054734-4 2007 Rimonabant, the first selective CB(1) receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Rimonabant 0-10 insulin Homo sapiens 162-169 18161262-6 2007 In addition, treatment with rimonabant had beneficial effects on insulin resistance, HDL-cholesterol and hypertriglyceridaemia. Rimonabant 28-38 insulin Homo sapiens 65-72 17292044-6 2007 Rimonabant is a selective cannabinoid-1 receptor antagonist and is the first compound of its type to test the hypothesis that down-regulating an overactive endocannabinoid system could have therapeutic benefit not only for weight loss but also for the atherogenic dyslipidemia and insulin resistance that cluster with abdominal obesity in particular. Rimonabant 0-10 insulin Homo sapiens 281-288 17292044-8 2007 Early human trials with rimonabant have confirmed significant reductions in weight, as well as favorable changes in atherogenic dyslipidemia, insulin resistance, and markers of inflammation. Rimonabant 24-34 insulin Homo sapiens 142-149 27208730-6 2016 Strikingly, this anti-insulin action of dexamethasone was also blocked by two CB1 cannabinoid receptor (CB1R) antagonists, O-2050 (500nM) and SR141716A (500nM), as well as by tetrahydrolipstatin (10muM), an inhibitor of diacylglycerol lipases-the enzymes responsible for the synthesis of the endocannabinoid, 2-arachidonoyl-glycerol (2-AG). Rimonabant 142-151 insulin Homo sapiens 22-29 17948364-5 2007 Patients treated with rimonabant also demonstrated statistically significant improvement in high-density lipoprotein cholesterol levels, triglyceride levels, and insulin resistance, as well as a reduced overall prevalence of metabolic syndrome. Rimonabant 22-32 insulin Homo sapiens 162-169 15836887-7 2005 Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome. Rimonabant 0-10 insulin Homo sapiens 134-141